Clinical trial · Observational
Prevalence of Creatinine Phosphokinase Increase in Patients With Solid Tumors Treated by Inhibitors of Tyrosine Kinases
National Study of Prevalence of Creatinine Phosphokinase (CPK) Increase in Patients With Solid Tumors Treated by Inhibitors of Tyrosine Kinases (TKI)
NCT01248429CI-TRIAL-00105555TKI-CPKcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study describes the elevation of CPK in patient treated for solid tumors by TKI
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Solid Tumor | Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Clinical exam | Other | — | UNRESOLVED |
| CPK dosage | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Patient treated by TKI
- description
- Any patient with solid tumor and treated by Thyrosine Kinase Inhibitor for at least 1 week
- interventionNames
- Biological: CPK dosage
- Other: Clinical exam
Primary outcomes (1)
- measure
- To evaluate the prevalence of the CPK increase
- timeFrame
- Within 3 days after a clinical exam
- description
- Dosage of CPK during standard blood sampling. The increase of CPK is defined when CPK value \> USL
Secondary outcomes (1)
- measure
- Correlation myalgia/CPK increase
- timeFrame
- During the clinical exam
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with solid tumor treated by inhibitor of tyrosin kinase for at least 1 week * Patient examined AND with a routine blood test planned * Patient informed of procedure for the study who was not opposed to it Exclusion Criteria: * Patient treated for malignant hemopathy * Patient no treated by inhibitor of thyrosine kinase or for less than 1 week * Patients with no routine blood laboratory tests planned
References
Publications (0)
Data not yet available
No reference posted for this study.